Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
EAGAN, Minn., Sept. 28, 2017 -- Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera’s novel phase 2 cancer immunotherapy. These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI-EORTC will feature initial translational research from Biothera’s ongoing phase 2 clinical study combining Imprime PGG and Merck’s anti-PD-1 antibody, Keytruda®, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.
American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, Boston, MA, October 1-4, 2017
| Session Date & Time | Monday, October 2, 2017, 5:30pm to 7:30pm ET |
| Session | Poster Session A |
| Presentation Title | Imprime PGG, a soluble yeast β-glucan PAMP, synergizes with anti-PD-1 antibody to enhance CD8 T cell anti-tumor immunity |
| Session Location | Boston Marriott Copley Place, Back Bay |
| Abstract Number | A18 |
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, October 26-30, 2017
| Session Date & Time | Saturday, October 28, 2017, 12:30pm-4:00pm, ET |
| Session | Immune Modulators, Late-Breaking Poster Session A |
| Presentation Title | Imprime PGG (Imprime) plus pembrolizumab (PEM): a phase 2 immunotherapeutic combination in patients selected for an Imprime-specific biomarker |
| Session Location | Hall E, Pennsylvania Convention Center |
| Abstract Number | LB-A31 |
| Session Date & Time | Sunday, October 29, 2017, 12:30pm to 4:00pm ET |
| Session Category | Immune Modulators |
| Session Title | Poster Session B |
| Presentation Title | Imprime PGG, a soluble yeast β-glucan PAMP, activates both innate and adaptive immune effector cells, resulting in enhanced antitumor responses that synergize with anti-PD-1 antibody therapy |
| Session Location | Hall E, Pennsylvania Convention Center |
| Poster Board Number | 9 |
| Abstract Number | B009 |
Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting, National Harbor, MD, November 8-12, 2017
| Session Date & Time | Saturday, November 11, 2017, 12:30 – 2pm and 6:30 – 8pm ET |
| Presentation Titles: | Increasing the levels of anti-beta glucan antibodies by administration of intravenous immunoglobulin (IVIG) induces immunopharmacodynamic (IPD) responses of a novel immunotherapeutic Imprime PGG |
| Session Location: | Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall DE |
| Abstract Number: | P74 |
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact:
David Walsh
Biothera Pharmaceuticals, Inc.
651-256-4606
[email protected]
